DS
RPTX

David Shaw’s Repare Therapeutics RPTX Stock Holding History

David Shaw’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-149,748
Closed -$515K – 4800
2024
Q3 		$515K Buy
149,748
+174
+0.1% +$573 ﹤0.01% 3688
2024
Q2 		$494K Buy
149,574
+29,441
+25% +$105K ﹤0.01% 3631
2024
Q1 		$566K Buy
120,133
+42,954
+56% +$275K ﹤0.01% 3417
2023
Q4 		$563K Buy
+77,179
New +$432K ﹤0.01% 3457
2023
Q3 		– Sell
-11,895
Closed -$126K – 4452
2023
Q2 		$126K Sell
11,895
-31,858
-73% -$328K ﹤0.01% 3809
2023
Q1 		$431K Sell
43,753
-63,521
-59% -$729K ﹤0.01% 3623
2022
Q4 		$1.58M Buy
107,274
+41,890
+64% +$627K ﹤0.01% 3120
2022
Q3 		$793K Sell
65,384
-8,857
-12% -$114K ﹤0.01% 3751
2022
Q2 		$1.04M Buy
+74,241
New +$874K ﹤0.01% 3611

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

David Shaw's RPTX Position: Q4 2024 in Review

David Shaw sold out of Repare Therapeutics (RPTX) in Q4 2024, closing a stake of 149,748 shares — an estimated $515K sold.

David Shaw first reported a position in RPTX in Q2 2022 and held it in 9 quarters. The position peaked at $1.58M in Q4 2022. 54 funds tracked by Wall St. Rank hold RPTX as of Q4 2024.

  • David Shaw reported no remaining Repare Therapeutics position as of Q4 2024 after selling out during the quarter.
  • David Shaw sold 149,748 Repare Therapeutics shares in Q4 2024, an estimated $515K.
  • David Shaw first reported a position in Repare Therapeutics in Q2 2022 and held it in 9 quarters.
  • David Shaw's Repare Therapeutics position peaked at $1.58M in Q4 2022.
  • 54 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2024.

Based on D.E. Shaw & Co's 13F filing for Q4 2024, filed 14 Feb 2025.